Catalyst Wire Dossier Catalyst Wire Dossier

REYVOW

Lasmiditan · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for REYVOW, covering 2019-10-11 to 2022-09-15. Get the full timeline:

Most recent: FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)

See pricing